FTH

Faeth Therapeutics, Inc.

Tremor tracks 2 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

2 insiders sold shares within a monthSince Jun 1, 2026+1.6

Trials

FTHFaeth Therapeutics
2Calm
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Signing up patientsPhase 1/232 patientsMain results: May 2029
FTHFaeth Therapeutics
2Calm
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Signing up patientsPhase 240 patientsMain results: Sep 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

4 sales (4 not pre-planned) · 23 purchases

STEPHENSON BRIAN CChief Financial Officer · Jul 1, 2026Bought 4,400 sharesabout $103 thousand ·
STEPHENSON BRIAN CChief Financial Officer · Jul 1, 2026Bought 600 sharesabout $15 thousand ·
STEPHENSON BRIAN CChief Financial Officer · Jun 30, 2026Bought 1,910 sharesabout $44 thousand ·
STEPHENSON BRIAN CChief Financial Officer · Jun 30, 2026Bought 1,638 sharesabout $39 thousand ·
STEPHENSON BRIAN CChief Financial Officer · Jun 30, 2026Bought 4,255 sharesabout $106 thousand ·
STEPHENSON BRIAN CChief Financial Officer · Jun 29, 2026

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.

FTH